Chemomab Therapeutics Q3 2023 Gaap EPS $(0.34) Misses $(0.02) Estimate
Portfolio Pulse from saritha@benzinga.com
Chemomab Therapeutics reported Q3 2023 GAAP EPS of $(0.34), missing the analyst consensus estimate of $(0.02) by 1600 percent. However, this represents a 51.43 percent increase over losses of $(0.70) per share from the same period last year.
November 09, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chemomab Therapeutics' Q3 2023 earnings missed estimates significantly, which could negatively impact investor sentiment and the stock price in the short term.
Chemomab Therapeutics reported a significant miss on its Q3 2023 earnings, which is likely to negatively impact investor sentiment. Despite the YoY improvement, the miss against estimates is a negative signal that could lead to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100